Platelet-rich fibrin (PRF): a growth factor-rich biomaterial. Part 1 – the platelet concentrates milieu & review of the literature

Jonathan Du Toit,1 Howard Gluckman,2 Maurice Salama3

Keywords: Platelet-rich fibrin (PRF), platelet concentrates, growth factors, intraoral grafting, augmentation

Introduction
The use of platelet concentrates in healing and augmentation has been reported on for more than forty years.1-4 Their preparations have evolved yet all methods involve the centrifugation of a patient’s own blood, with or without additional preparation steps and additives, to derive an autogenous biomaterial.5 Whilst their use is widely reported in the literature in the treatment of sports tendon injuries, surface wound treatment, and plastic surgery, their most widespread application are as intraoral graft materials for tissue regeneration and pre-implant surgery. Of the more widely published among these platelet concentrates as an autogenous graft material used in oral surgery and implantology, is Choukroun’s PRF – a leukocyte and platelet-rich fibrin.6 Choukroun’s PRF is derived from centrifuging a sample of the recipient patient’s own blood and separating it into platelet-poor plasma, a platelet-rich fibrin clot, and red blood cells.7 PRF is autogenous since the blood sample is derived from the patient requiring the augmentation procedure, processed externally, free of additives, and then as with autografts it is re-implanted to the surgical site in the same patient. However, there currently is no gold standard as to which platelet concentrate supersedes all others as an intraoral graft material or as a biomaterial to accelerate healing. PRF in implant surgery has extensively been reported on over the last two decades, yet there is a paucity of literature reporting objective, histological evaluation of tissue resulting from PRF grafted intraoral sites.8-13 Aside from the hype generated in recent years around this biomaterial, it is pertinent for the clinician treating patients with PRF to have a sound understanding of its place among the platelet concentrates, understand its biology and applications, have a knowledge of the current and available literature, and be aware of the material’s limitations as well its potential.

Intraoral augmentation
Augmentation of an intraoral site in pre-implant / pre-restorative surgery requires selection among a host of techniques and materials.14 Whatever the technique, a graft material is generally required and the implications of each are to be well understood by the clinician. Selecting allograft, xenograft, or alloplastic material is at an increased treatment cost, may be contraindicated by the patient’s religious beliefs, and requires the materials to be available on hand. Autogenous bone remains the literature supported gold standard of care due to its superior osteogenic, osteoinductive, osteoconductive, and non-immunogenic properties, despite its faster resorption in comparison to xenogeneic or alloplastic materials.15 In recent years platelet concentrates have widely been proposed as viable autogenous materials for use in periodontal, oral and implant surgery. The literature is abundant predominantly with Anitua’s PRGF and Choukroun’s...
Classification of platelet concentrates

The invention of platelet concentrates originated from the treatment of haemorrhagic disorders, by the separation of whole blood to harvest platelets for transfusion to treat leukaemias, thrombocytopenias, etc. Matras first introduced into the literature the use of ‘fibrin glues’ as a surgical haemostatic agent in the 1970s. fibrin glues were thought to possibly stimulate healing, and later with the discovery of growth factors contained within platelet granules, such as transforming growth factor (TGF-β1), did it spur the pursuit of platelet concentrates’ use in tissue and bone regeneration.

Platelet-rich plasma (PRP) was first introduced into the literature for use in oral surgery by Whitman in 1997. Anitua in 1999 introduced another variation of these concentrates, naming it Platelet Rich in Growth Factors (PRGF). Choukroun thereafter introduced platelet-rich fibrin (PRF) in 2001. Clinicians have since invented their own protocols for platelet concentrates and so too have commercial organizations introduced products and equipment to purpose their own versions of these materials.

Among the diverse variations in the literature, Choukroun’s PRF is possibly one of the more widely published techniques. Nevertheless, not only is the platelet concentrate nomenclature complex, but also their preparation protocols. They differ in their biology, in their concentrate constituent, as well as in their applications. Moreover, little to no literature concisely reports on their exact constitutions. Clinical applications of these by case series and reports may be abundant, but not a single systematic review or meta-analysis of their ultrastructural morphology and composition.
exists. This platelet concentrate milieu may well confuse the clinician. Whilst not exhausting the inquiry, a classification derived from a review of the literature identifies four main types of platelet concentrate products based on their fibrin architecture and cell content, namely:

1. Pure platelet-rich plasma (P-PRP)
2. Leukocyte and platelet-rich plasma (L-PRP)
3. Pure platelet-rich fibrin (P-PRF)
4. Leukocyte and platelet-rich fibrin (L-PRF)

Platelet-rich plasma (PRP) was established in the literature in the 1970s in the directives of the American Association of Blood Banks, the American National Red Cross Blood program, and the Canadian Red Cross Blood Transfusion Program. PRP was used in replacement therapy following blood loss. It was derived by centrifugation, with authors reporting in succession on modifications of centrifugation speed and duration to obtain higher platelet yield. This period notes the first mention of the term ‘buffy coat’, what we now know to be platelet-rich fibrin (PRF) today. Nearly 40 years later, clinicians and scientists continue to proffer new centrifugation techniques. P-PRP was first mentioned in the literature for its wound healing and therapeutic use in 1950. Niiekisch was the first to report on its application in managing haemorrhaging disorders in maxillofacial and oral surgery, in 1980. Only in 1997 again did Whitman and co-workers report on P-PRP as a ‘fibrin glue’ and haemostatic agent in oral surgery, though proposing for the first time its potential to improve healing following oral surgery. Marx and co-workers then in 1998 reported an increase in both bone formation and density as a result of platelets releasing growth factors, thus reinforcing P-PRP use in intraoral grafting, augmentation, regenerative therapy.

**i. Pure platelet-rich plasma (P-PRP)**

P-PRP are products low in or without leukocyte content, and have a low-density fibrin network after preparation. All products within this group are a liquid or gel that can be injected or administered topically. As P-PRP preparation techniques developed to the present day, from the literature they may be subdivided into automated and manual. The automated P-PRP variants are typically commercial products. One of the first among such automated P-PRP was the Curasan kit introduced in 2001, though the product has long since been discontinued. Similarly, the Platelet Concentrate Collection System (PCCS) for P-PRP was launched in 2002 (3i Implant Innovations). This product too has since been discontinued. The Vivostat PRF system (Vivolution, Denmark) was later introduced in 2005 as a fully automated production of autogenous fibrin sealant. The confusion in nomenclature becomes evident. Whilst the manufacturer names the concentrate a PRF, as well as an ‘autogenous fibrin sealant’, by being leukocyte poor and having a low density fibrin content it is classified a P-PRP. The Vivostat PRF system is probably one of the more prominent and commercially used P-PRP products available. Its large processing unit acts as a cell separator of a patient’s whole blood, applying multiple centrifugations, and incrementally introducing additives such as an acetate buffer. Whilst the temperature is maintained at 36 °C, the plasma is separated out and fibrinogen activator is added. Fibrin and serum are separated and the steps are repeated whilst the acetate buffer is added. The buffer dissolves the fibrin, and the final product is ready for application. Supporting its categorization as a P-PRP is this final step of removing the active fibrin component.

Of the manual preparations of P-PRP, Anitua’s technique
introduced in 1999 is possibly the most widely published. Like other platelet concentrates, the preparation of PRGF involves the centrifugation of whole blood, but in several smaller blood tubes, to form three layers – red blood cells, a buffy coat, and acellular plasma. Anitua considers the upper portion of the acellular plasma as being platelet poor. This plasma is pipetted off and discarded. The lower portion is considered platelet rich, and thus the PRGF. Manually pipetting this plasma off relies on the operator’s discretion. PRGF from several tubes are then combined and fibrin polymerization is induced by adding 10% calcium chloride. After ± 20 minutes the PRGF gel is formed and ready for use.

ii. Leukocyte and platelet-rich plasma (L-PRP)

L-PRP comprises the largest group of commercially available products among the four main platelet concentrate types. L-PRP products contain leukocytes and have a low-density fibrin network, and all products within this group are also used as a liquid or gel administered by injection or topically. An example of this system is Harvest SmartPrep (Harvest Technologies). It is essentially a modified centrifuge that instead of receiving blood tubes, separates whole blood in a dual-chamber capsule containing a “floating shelf”. Another very similar L-PRP product that centrifuges a capsule containing a “floating buoy” is the GPS III (Biotest). These floating devices claim to adapt to the cellular density that is patient specific to separate plasma, platelets, and leukocytes, from red blood cells.

iii. Pure platelet-rich fibrin (P-PRF)

P-PRF are products without leukocytes and have a high-density fibrin network. Thus, these are applied as dense gels and are not injectable. Only one commercially available product represents this group: Fibrinet PRFM (Cascade Medical). It consists of a wholly disposable kit, including an anticoagulant containing blood tube. The process involves centrifugation followed by multiple transfer steps before its administration.

iv. Leukocyte and platelet-rich fibrin (L-PRF)

L-PRF products contain leukocytes within a high-density fibrin network. They are mostly solid or dense gels and cannot be injected (although Choukroun has developed an injectable variant, i-PRF which remains in the testing stages). Of the L-PRF products, Choukroun’s PRF (Process, France) is possibly the most widely reported on. A near identical product is Intra-Spin L-PRF (Intra-Lock Inc.). L-PRF products are discernible from other platelet concentrates as being entirely autogenous, have neither anticoagulant nor other additives, and consist of only a one-step centrifugation process. Production of PRF does not strictly require any commercial materials. Any centrifuge calibrated to ± 400 g of force and set for 10 minutes can derive PRF from a sample of a patient’s whole blood collected in an additive free blood tube (Fig. 1). The clinician is to note that Choukroun has updated his protocol, proffering a newer “Advanced PRF” or A-PRF protocol, with a lower centrifugation RPM for a longer cycle duration.

Platelet-rich fibrin biology

The basic purpose of manipulating a sample of a patient’s whole blood to derive a platelet concentrate, is to segregate the blood’s constituents, retain a portion and discard others, promote activation of the retained portion, and then therapeutically deliver this to a treatment site within a patient. Centrifugation or a variation thereof is integral to all the techniques. The separating of whole blood is done chemically, mechanically, or as a combination. All the L-PRF and P-PRF...
injured endothelium and from activated platelets bound to exposed collagen and each other. In vitro when whole blood is centrifuged, centrifugal forces expose platelets to the tube wall. This contact of platelets with each other and the tube wall results in their activation.

In the absence of anticoagulant this platelet activation is immense. Activated platelets up-regulate the tissue factor expression of leukocytes in the tube. As platelets become activated, their granules, specifically α-granules burst, releasing cytokines and tissue factors, β-thromboglobulin, fibronectin, thrombospondin, fibrinogen, coagulation factors, growth promoters, fibrinolysis inhibitors, and immunoglobulins (Fig. 4). Each of these has a highly specific function in tissue healing, in haemostasis, inflammation and proliferation.

Degranulation releases cytokines that promote cell migration and proliferation in the clot's fibrin matrix, promoting the early stages of healing. Of these, transforming growth factor β-1 (TGF-β1), platelet derived growth factor (PDGF), and insulin-like growth factors I and II (IGF-I, II) are the most prominent. TGF-β1 has extremely varied effects. In bone healing it may either stimulate osteoblasts or cause their inhibition, depending on its concentration, on the matrix environment, and the cell types present. Regardless, it is a powerful fibrosis agent for most cell types and induces rapid and substantial endochondral bone (in primates). TGF-β1 will greatly induce collagen I and fibronectin synthesis from fibroblasts and osteoblasts. It is considered an inflammatory mediator by its capacity to induce fibrous healing, though its regulatory mechanisms are complex.

Insulin-like growth factors (IGFs) I and II positively regulate...
both proliferation and differentiation of a majority of cell types by acting as tissue growth factors and hormones of energy metabolism. They stimulate cellular proliferation during healing over the long term. Whilst not only platelets but many tissues release IGF-I, it has been shown to increase serum levels of alkaline phosphatase, and serum procollagen – both which stimulate osteoblastic activity.

Platelet-derived growth factors (PDGF) are essential regulators of the migration and proliferation of mesenchymal cells. PDGF induce tissue repair mechanisms and promote fibroblast proliferation, collagen production, and are powerful mitogens for angiogenesis. Similar to transforming growth factors, they may also stimulate or inhibit. This regulation is central to tissue remodelling.

Whilst forming the PRF clot, the activated fibrin has been shown to enmesh glycosaminoglycans, namely heparin and hyaluronic acid (Fig. 5). These have a strong affinity for binding cells and cytokines – supporting cell migrations during the healing phase, and wholly incorporating the cytokinins into their fibrils in high concentrations. PRP is low in fibrin density, and as such cytokines are more freely available within the material. These cytokines’ release and activity are measurably high in PRF, intense and short-lived over the first days of healing. By contrast the cytokinins entrapped within the fibrin matrix of a PRF clot allow for a slower and long term release.

The net result of this PRF biology is the preparation of a biomaterial, dense and resilient in its activated fibrin structure, and richly incorporated by leukocytes and platelets (Fig. 6). The implantation of such a biomaterial may deliver the slow release of growth promoting factors and cytokines to an area of healing (Fig. 7).

Conclusion

PRF has in recent years become popularized as a biomaterial rich in growth factors valuable to pre-implant and pre-restorative surgery. In theory the biology behind the technique is literature based, the material does contain growth factors, and growth factors do aid healing. Definitive, histological evidence of its healing promoting effect on either bone or soft tissue is not conclusive. The material’s potential remains significant and yet additional histological evidence and clinical trials are needed to further validate.

Acknowledgements

Kind permission for usage of figure 2 by Dr Cliff Leachman, BC, Canada, figures 4 and 5 by Antoinette Buys and coworkers, University of Pretoria, and figure 6 by Dr. Andre E. Brown and Prof. John Weisel, University of Pennsylvania School of Medicine.

References


from: http://www.biomet.com/biologics/whyGPS.cfm